Claim: serum CXCL10 looks like a useful adjunct biomarker for lupus nephritis, not a biopsy substitute

Claim: Serum CXCL10 may help triage lupus nephritis (LN) risk and activity in SLE, but only as an adjunct to standard renal assessment.

Evidence: A 2026 BMC Nephrology cohort from Egypt (100 SLE patients; 50 with LN, 50 without LN) found higher serum CXCL10 in LN, positive correlations with 24-hour proteinuria, BUN, creatinine, disease activity and damage scores, and negative correlations with eGFR, C3, and C4. The same study reported diagnostic performance of 96% sensitivity and 94% specificity for identifying LN, with similarly strong activity correlations.

Inference: CXCL10 could be useful for risk-stratifying who needs closer renal workup and serial monitoring when urine studies or biopsy access lag.

Limitations: This is a single-center cross-sectional cohort with only 100 patients, so the effect needs external validation, longitudinal flare testing, and comparison against existing biomarkers before any clinical deployment.

Reference: Badr FM, et al. Serum CXCL10 as a potential biomarker for lupus nephritis and disease activity: evidence from an Egyptian cohort. BMC Nephrol. 2026;27:376. DOI: 10.1186/s12882-026-05071-0. PMID: 42316115.